A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ

SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI

Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow

Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6

• E-CONGRESS

Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc

• E-CONGRESS

This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4

This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T

• E-CONGRESS

nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5

• E-CONGRESS

COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396 https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K

• E-CONGRESS

Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw

• EULAR Abstract Archive

This UK study to determine neutrophil function in PsA found that SEC does not affect neutrophil host defense. Check out #ABO115 for further details. An interesting find w/ regard to the inflammatory blockade and mediators of dz. #EULAR2020 @RheumNow https://t.co/EwLdlKU06A

• EULAR Abstract Archive

IL-36 as a new biomarker/tx target in SpA? Check out this interesting in vitro study out of the UK and the IL-36 upstream induction of the IL-17/IL-23 pathway. #EULAR2020 @RheumNow #SAT0356 https://t.co/YTVepexd45

• EULAR Abstract Archive

Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow

• EULAR Abstract Archive

Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n

• EULAR Abstract Archive

“Let’s consider treating nr-ax SpA and axSpA as serious, similar entities for better treatment options for our patients.” Dr. D. Poddubnyy discussing EXCEED study results and extrapolation of data. #EULAR2020 @RheumNow